Breakthrough Device Designation – FDA Fast-Track Pathway

The Breakthrough Device Designation program by the US FDA speeds up the development and review of medical devices that provide more effective diagnosis or treatment for life-threatening or permanently debilitating conditions. The purpose of Breakthrough Device Designation is to give patients faster access to innovative technologies.

To qualify for Breakthrough Device Designation, a device must demonstrate a reasonable expectation of improved clinical outcomes and meet at least one criterion: breakthrough technology, no approved alternative, significant advantage over existing options, or availability in the best interest of patients.

Manufacturers can apply for Breakthrough Device Designation through the FDA’s Q-Submission program. The FDA generally responds within 60 days, and there are no user fees. Receiving Breakthrough Device Designation ensures priority review but does not automatically determine the final regulatory pathway (PMA, 510(k), or De Novo).